Chemotherapy and targeted molecular therapies for brain metastases

References

• Norden AD, Wen PY, Kesari S. Brain metastases. Curr. Opin. Neurol.18(6), 654–661 (2005).
   PubMed Web of Science ®Google Scholar
• Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J. Neurooncol.75(1), 5–14 (2005).
   PubMed Web of Science ®Google Scholar
• Davey P. Brain metastases: treatment options to improve outcomes. CNS Drugs16(5), 325–338 (2002).
   PubMed Web of Science ®Google Scholar
• Lassman AB, DeAngelis LM. Brain metastases. Neurol. Clin.21(1), 1–23, VII (2003).
   PubMed Web of Science ®Google Scholar
• Donelli MG, Zucchetti M, D’Incalci M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother. Pharmacol.30(4), 251–260 (1992).
   PubMed Web of Science ®Google Scholar
• Soffietti R, Costanza A, Laguzzi E, Nobile M, Ruda R. Radiotherapy and chemotherapy of brain metastases. J. Neurooncol.75(1), 31–42 (2005).
   PubMed Web of Science ®Google Scholar
• Lesser GJ. Chemotherapy of cerebral metastases from solid tumors. Neurosurg. Clin. N. Am.7(3), 527–536 (1996).
   PubMed Web of Science ®Google Scholar
• Postmus PE, Haaxma-Reiche H, Sleijfer DT, Kirkpatrick A, McVie JG, Kleisbauer JP. High dose etoposide for brain metastases of small cell lung cancer. A Phase II study. The EORTC Lung Cancer Cooperative Group. Br. J. Cancer59(2), 254–256 (1989).
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin.53(1), 5–26 (2003).
   PubMed Web of Science ®Google Scholar
• Wen PY MBP, Loeffler JS. Metastatic brain cancer. De Vita VT Jr, HS, Rosenberg SA (Eds). Lippincott Williams and Wilkins, PA, USA (1999).
   Google Scholar
• Tosoni A, Ermani M, Brandes AA. The pathogenesis and treatment of brain metastases: a comprehensive review. Crit. Rev. Oncol. Hematol.52(3), 199–215 (2004).
   PubMed Web of Science ®Google Scholar
• Katz A, Zalewski P. Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib. Br. J. Cancer89(Suppl. 2), S15–S18 (2003).
   PubMed Web of Science ®Google Scholar
• Kleisbauer JP, Guerin JC, Arnaud A, Poirier R, Vesco D. Chemotherapy with high-dose cisplatin in brain metastasis of lung cancers. Bull. Cancer77(7), 661–665 (1990).
   PubMed Web of Science ®Google Scholar
• Boogerd W, van der Sande JJ, van Zandwijk N. Teniposide sometimes effective in brain metastases from non-small cell lung cancer. J. Neurooncol.41(3), 285–289 (1999).
   PubMed Web of Science ®Google Scholar
• Kleisbauer JP, Vesco D, Orehek J et al. Treatment of brain metastases of lung cancer with high doses of etoposide (VP16–213). Cooperative study from the Groupe Franais Pneumo-Cancerologie. Eur. J. Cancer Clin. Oncol.24(2), 131–135 (1988).
   PubMedGoogle Scholar
• Pujol JL, Monnier A, Berille J et al. Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer. Br. J. Cancer69(6), 1136–1140 (1994).
   PubMed Web of Science ®Google Scholar
• Cortes J, Rodriguez J, Aramendia JM et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology64(1), 28–35 (2003).
   PubMed Web of Science ®Google Scholar
• Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer85(7), 1599–1605 (1999).
   PubMed Web of Science ®Google Scholar
• Bernardo G, Cuzzoni Q, Strada MR et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a Phase II study. Cancer Invest.20(3), 293–302 (2002).
   PubMed Web of Science ®Google Scholar
• Cotto C, Berille J, Souquet PJ et al. A Phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur. J. Cancer32A 1), 69–71 (1996).
   PubMed Web of Science ®Google Scholar
• Minotti V, Crino L, Meacci ML et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer20(2), 93–98 (1998).
   PubMed Web of Science ®Google Scholar
• Kaba SE, Kyritsis AP, Hess K et al. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J. Clin. Oncol.15(3), 1063–1070 (1997).
   PubMed Web of Science ®Google Scholar
• Malacarne P, Santini A, Maestri A. Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology53(3), 210–213 (1996).
   PubMed Web of Science ®Google Scholar
• Newton HB, Slivka MA, Volpi C et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. J. Neurooncol.61(1), 35–44 (2003).
   PubMed Web of Science ®Google Scholar
• Omuro AM, Raizer JJ, Demopoulos A, Malkin MG, Abrey LE. Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a Phase I trial. J. Neurooncol.78(3), 277–80 (2006).
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Bafaloukos D, Kosmidis P et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann. Oncol.12(2), 249–254 (2001).
   PubMed Web of Science ®Google Scholar
• Dziadziuszko R, Ardizzoni A, Postmus PE et al. Temozolomide in patients with advanced non-small cell Lung Cancer with and without brain metastases. A Phase II study of the EORTC Lung Cancer Group (08965). Eur. J. Cancer39(9), 1271–1276 (2003).
   PubMed Web of Science ®Google Scholar
• Giorgio CG, Giuffrida D, Pappalardo A et al. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: Phase II study. Lung Cancer50(2), 247–254 (2005).
   PubMed Web of Science ®Google Scholar
• Friedman HS EB, Reardon D et al. Phase II trial of temozolomide for patients with progressive brain metastases. American Society of Clinical Oncology 39th Annual Meeting, Chicago, Illinois.Proc. ASCOMay 31 – June 3 22, 102 (2003).
   Google Scholar
• Giannitto-Giorgio C CS, DiBlasi C et al. Temozolomide shows promising activity against pretreated brain recurrences of NSCLC. Preliminary results of a Phase II trial. American Society of Clinical Oncology 38th Annual Meeting, Orlando, FL, USA 18–21 May 2002.Proc. ASCO21(pt 2), 2406 (2002) (Abstract 2779).
   Google Scholar
• Omuro AM, Raizer JJ, Demopoulos A, Malkin MG, Abrey LE. Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a Phase I trial. J. Neurooncol.78(3), 277–280 (2006).
   PubMed Web of Science ®Google Scholar
• Siena S S LG, Baietta E et al. Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer and non-small cell lung cancer. American Society of Clinical Oncology 39th Annual Meeting, Chicago, IL, USA 31 May-3 June 2003. Proc. ASCO22, 102 (2003) (Abstract 407).
   Google Scholar
• Tolcher AW, Gerson SL, Denis L et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer88(7), 1004–1011 (2003).
   PubMed Web of Science ®Google Scholar
• Ebert BL, Niemierko E, Shaffer K, Salgia R. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist8(1), 69–75 (2003).
   PubMed Web of Science ®Google Scholar
• Fleckenstein K, Hof H, Lohr F, Wenz F, Wannenmacher M. Prognostic factors for brain metastases after whole brain radiotherapy. Data from a single institution. Strahlenther. Onkol.180(5), 268–273 (2004).
   PubMed Web of Science ®Google Scholar
• Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys.37(4), 745–751 (1997).
   PubMed Web of Science ®Google Scholar
• Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int. J. Radiat. Oncol. Biol. Phys.47(4), 1001–1006 (2000).
   PubMed Web of Science ®Google Scholar
• Nieder C, Nestle U, Walter K, Niewald M, Schnabel K. Dose/effect relationships for brain metastases. J. Cancer Res. Clin. Oncol.124(6), 346–350 (1998).
   PubMed Web of Science ®Google Scholar
• Kocher M, Eich HT, Semrau R, Guner SA, Muller RP. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases. Strahlenther. Onkol.181(1), 20–25 (2005).
   PubMed Web of Science ®Google Scholar
• Lamond JP, Mehta MP, Boothman DA. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. J. Neurooncol.30(1), 1–6 (1996).
   PubMed Web of Science ®Google Scholar
• Lamond JP, Wang M, Kinsella TJ, Boothman DA. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys.36(2), 361–368 (1996).
   PubMed Web of Science ®Google Scholar
• Sauer R, Heuser A. Topoisomerase I inhibitor with potential radiosensitizing effect. Strahlenther. Onkol.173(3), 125–130 (1997).
   PubMedGoogle Scholar
• Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother. Pharmacol.37(3), 195–202 (1996).
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Luftner DI, Egorin MJ et al. The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid. Ann. Oncol.12(1), 119–122 (2001).
   PubMed Web of Science ®Google Scholar
• Wong ET, Berkenblit A. The role of topotecan in the treatment of brain metastases. Oncologist9(1), 68–79 (2004).
   PubMed Web of Science ®Google Scholar
• Schutte W, Manegold C, von Pawel JV et al. Topotecan – a new treatment option in the therapy of brain metastases of lung cancer. Front Radiat. Ther. Oncol.33, 354–363 (1999).
   PubMed Web of Science ®Google Scholar
• Antonadou D, Paraskevaidis M, Sarris G et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol.20(17), 3644–3650 (2002).
   PubMed Web of Science ®Google Scholar
• Verger E GM, Yaya R et al. Concomitant temozolomide (TMZ) and whole brain radiotherapy (WBRT) in patients with brain metastases (BM): randomized multicentric Phase II study. American Society of Clinical Oncology 39th Annual Meeting, Chicago, IL, USA, 31 May-3 June, 2003. Proc. ASCO22, 101 (2003) (Abstract 404).
   Google Scholar
• Antonadou D CN, Papasekvaidis M et al. Whole brain radiotherapy alone or in combination with temozolomide for brain metastases. A Phase III study. Proceedings of the American Society for Therapeutic Radiology and Oncology 44th Annual Meeting. Int. J. Radiat. Oncol. Phys.54(2S), 93 (2002) (Abstract 156).
   Google Scholar
• Dardoufous C MA, Skarleas C et al. Concomitant temozolomide (TMZ) and radiotherapy (RT) followed by adjuvant treatment with temozolomide in patients with brain metastases from solid tumors. American Society of Clinical Oncology 37th Annual Meeting, San Francisco, CA, 12–15 May, 2002. Proc. ASCO20, (Pt 2042), 2075b (2001) (Abstract 2048).
   Google Scholar
• Dawood S. RJ, Navaratnam S, Mihalcioiu C. Phase II study of concurrent temozolomide and whole brain radiation therapy in patients with brain metastasis. ASCO Annual Meeting Proceedings Part I 2006. J. Clin. Oncol.24(Suppl. 18), 1540 (2006).
   Google Scholar
• Guerrieri M, Wong K, Ryan G, Millward M, Quong G, Ball DL. A randomised Phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer46(1), 107–111 (2004).
   PubMed Web of Science ®Google Scholar
• Ushio Y, Arita N, Hayakawa T et al. Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery28(2), 201–205 (1991).
   PubMed Web of Science ®Google Scholar
• Robinet G, Thomas P, Breton JL et al. Results of a Phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) protocol 95–1. Ann. Oncol.12(1), 59–67 (2001).
   PubMed Web of Science ®Google Scholar
• Quadvlieg V BL, Gustin M, Barthelemy N. Frontline gemcitabine and cisplatin based chemotherapy in patients with NSCLC inoperable brain metastases. ASCO Annual Meeting Proceedings 2004J. Clin. Oncol.22, 14S (2004) (Abstract 7117).
   Google Scholar
• Sgouros J, Braun, M, Holmes M, Maraveyas A. A Phase I study of chemo-radiotherapy using gemcitabine as a radiosensitiser in patients with metastases to the brain. ASCO Annual Meeting Proceedings 2004 J. Clin. Oncol.22, S14 (2004) (Abstract 1570).
   Google Scholar
• Wagenius G, Brodin, O, Nyman, J et al. Radiotherapy vs. temozolomide in the treatment of patients with lung cancer and brain metastases: a randomized Phase II study. J. Clin. Oncol.24, S398 (2006) (Abstract 7136).
   Google Scholar
• Rodrigus P. Motexafin gadolinium: a possible new radiosensitiser. Expert Opin. Investig. Drugs12(7), 1205–1210 (2003).
   PubMed Web of Science ®Google Scholar
• Meyers CA, Smith JA, Bezjak A et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized Phase III trial. J. Clin. Oncol.22(1), 157–165 (2004).
   PubMed Web of Science ®Google Scholar
• Mehta MP, Rodrigus P, Terhaard CH et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol.21(13), 2529–2536 (2003).
   PubMed Web of Science ®Google Scholar
• Mehta M, Gervais R, Chabot P et al. Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: results of a Phase III trial J. Clin. Oncol.24, S367 (2006). (Abstract 7014)
   Google Scholar
• Newton HBVC, Burkart J. et al. Phase III randomized multicenter trial of surgical resection, BCNU-impregnated wafers, and irradiation versus surgical resection and irradiation alone for treatment of operable, solitary brain metastasis from systemic cancer. ASCO Annual Meeting Proceedings Part I 2006. J. Clin. Oncol.24, 18S (2006) (Abstract 11513).
   Google Scholar
• Wakelee HA, Sikic BI. Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. Clin. Lung Cancer7(Suppl. 1), S6–S12 (2005).
   Web of Science ®Google Scholar
• Larkin JM, Kaye SB. Epothilones in the treatment of cancer. Expert Opin. Investig. Drugs15(6), 691–702 (2006).
   PubMed Web of Science ®Google Scholar
• De Cesare M, Pratesi G, Perego P et al. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res.61(19), 7189–7195 (2001).
   PubMed Web of Science ®Google Scholar
• Goeminne H, van Meerbeeck JP. Pemetrexed in thoracic cancer. Expert Opin. Pharmacother.7(7), 917–928 (2006).
   PubMed Web of Science ®Google Scholar
• Dai H, Chen Y, Elmquist WF. Distribution of the novel antifolate pemetrexed to the brain. J. Pharmacol. Exp. Ther.315(1), 222–229 (2005).
   PubMed Web of Science ®Google Scholar
• Cascone T, Morelli MP, Ciardiello F. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. Ann. Oncol.17(Suppl. 2), II46–II48 (2006).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ardizzoni A, Soto-Parra H et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell Lung Cancer (NSCLC). Lung Cancer41(2), 227–231 (2003).
   PubMed Web of Science ®Google Scholar
• Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP. Gefitinib is active in patients with brain metastases from non-small cell Lung Cancer and response is related to skin toxicity. Lung Cancer47(1), 129–138 (2005).
   PubMed Web of Science ®Google Scholar
• Namba Y, Kijima T, Yokota S et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin. Lung Cancer6(2), 123–128 (2004).
   PubMedGoogle Scholar
• Poon AN, Ho SS, Yeo W, Mok TS. Brain metastasis responding to gefitinib alone. Oncology67(2), 174–178 (2004).
   PubMed Web of Science ®Google Scholar
• Roggero E, Busi G, Palumbo A, Pedrazzini A. Gefitinib (‘Iressa’, ZD1839) is active against brain metastases in a 77 year old patient. J. Neurooncol.71(3), 277–280 (2005).
   PubMed Web of Science ®Google Scholar
• Harita S, Mizuta A, Kuyama S, Kikuchi T. Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only. Int J. Clin. Oncol.10(1), 63–68 (2005).
   PubMedGoogle Scholar
• Hotta K, Kiura K, Ueoka H et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer46(2), 255–261 (2004).
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Kiura K, Ueoka H, Tabata M, Hamasaki S, Tanimoto M. Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer40(1), 73–76 (2003).
   PubMed Web of Science ®Google Scholar
• Villano JL, Mauer AM, Vokes EE. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann. Oncol.14(4), 656–658 (2003).
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann. Oncol.15(7), 1042–1047 (2004).
   PubMed Web of Science ®Google Scholar
• Shimato S, Mitsudomi T, Kosaka T et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro-oncol.8(2), 137–144 (2006).
   PubMed Web of Science ®Google Scholar
• Choong NW, Dietrich S, Seiwert TY et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat. Clin. Pract. Oncol.3(1), 50–57 (2006).
   PubMedGoogle Scholar
• Lai CS, Boshoff C, Falzon M, Lee SM. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax61(1), 91 (2006).
   PubMedGoogle Scholar
• Abigerges DK, Mokadem R, Chammas WS. Efficacy of erlotinib in the treatment of patients with brain metastasis from non small cell lung cancer. ASCO Annual Meeting Proceedings Part I 2006. J. Clin. Oncol.24, 18S (2006) (Abstract 17149).
   Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol.22(11), 2184–2191 (2004).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Brahmer J et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC 704865) in patients with advanced non-squamous non-small cell Lung Cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial – E4599. ASCO Annual Meeting Proceedings part I/II, 2005. J. Clin. Oncol.23, S16 (2005).
   Google Scholar
• Rini BI. Sorafenib. Expert Opin. Pharmacother.7(4), 453–461 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hoosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs15(5), 553–561 (2006).
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Belani CP, Bonomi P et al. A Phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of Avastin (bevacizumab) in combination with either chemotherapy (docetaxel or pemetrexed) or Tarceva (erlotinib hydrochloride) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. ASCO Annual Meeting Proceedings part I 2006 J. Clin. Oncol.24, S18 (2006) (Abstract 7062).
   Google Scholar
• Grossi F, Scolaro T, Tixi L, Loprevite M, Ardizzoni A. The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. Crit. Rev. Oncol. Hematol.37(1), 61–67 (2001).
   PubMed Web of Science ®Google Scholar
• Kristensen CA, Kristjansen PE, Hansen HH. Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J. Clin. Oncol.10(9), 1498–1502 (1992).
   PubMed Web of Science ®Google Scholar
• Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK. Primary chemotherapy of brain metastasis in small-cell lung cancer. J. Clin. Oncol.7(7), 916–922 (1989).
   PubMed Web of Science ®Google Scholar
• Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer45(Suppl. 2), S253–S257 (2004).
   PubMed Web of Science ®Google Scholar
• Seute T, Leffers P, Wilmink JT, ten Velde GP, Twijnstra A. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J. Clin. Oncol.24(13), 2079–2083 (2006).
   PubMed Web of Science ®Google Scholar
• Korfel A, Oehm C, von Pawel J et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre Phase II study. Eur. J. Cancer38(13), 1724–1729 (2002).
   PubMed Web of Science ®Google Scholar
• Postmus PE, Haaxma-Reiche H, Smit EF et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy – a Phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol.18(19), 3400–3408 (2000).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ. The role of chemotherapy in brain metastases. Eur. J. Cancer39(15), 2114–2120 (2003).
   PubMed Web of Science ®Google Scholar
• Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer97(12), 2972–2977 (2003).
   PubMed Web of Science ®Google Scholar
• Puente Vazquez J, Lopez-Tarruella Cobo S, Garcia-Saenz JA et al. Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies. Clin. Transl. Oncol.8(1), 50–53 (2006).
   PubMedGoogle Scholar
• Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer101(4), 810–816 (2004).
   PubMed Web of Science ®Google Scholar
• Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer58(4), 832–839 (1986).
   PubMed Web of Science ®Google Scholar
• Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer69(4), 972–980 (1992).
   PubMed Web of Science ®Google Scholar
• Cocconi G, Lottici R, Bisagni G et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest.8(3–4), 327–334 (1990).
   PubMed Web of Science ®Google Scholar
• Trudeau ME WB, Yelle L et al. Temozolomide in metastatic breast cancer (MBC): a Phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Proc. Am. Soc. Clin. Oncol.21 (2002) (Abstract.2031).
   Google Scholar
• Arena FP K-SA, Treanor S et al. Efficacy of temozolomide in heavily pre-treated patients with stage IV breast cancer with or without brain metastasis. Proc. Am. Soc. Clin. Oncol.22, 54 (2003) (Abstract 215).
   Google Scholar
• Trudeau ME, Crump M, Charpentier D et al. Temozolomide in metastatic breast cancer (MBC): a Phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG). Ann. Oncol.17(6), 952–956 (2006).
   PubMed Web of Science ®Google Scholar
• Martinez-Cedillo J AA LF et al. Temozolomide (TMZ) in metastatic breast cancer (BC) to central nervous system (CNS). Proc. Am. Soc. Clin. Oncol.22 (2003) (Abstract 350).
   Google Scholar
• O’Shaughnessy JA. The evolving role of capecitabine in breast cancer. Clin. Breast Cancer4 (Suppl. 1), S20–S25 (2003).
   PubMedGoogle Scholar
• Rogers LR, Remer SE, Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro-oncol.6(1), 63–64 (2004).
   PubMed Web of Science ®Google Scholar
• Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr. Med. Assoc. J.5(11), 833–834 (2003).
   PubMed Web of Science ®Google Scholar
• Fabi A, Vidiri A, Ferretti G et al. Dramatic regression of multiple brain metastases from breast cancer with capecitabine: another arrow at the bow? Cancer Invest.24(4), 466–468 (2006).
   PubMed Web of Science ®Google Scholar
• Hikino H, Yamada T, Johbara K, Obayashi N, Ozaki N. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast15(1), 97–99 (2006).
   PubMed Web of Science ®Google Scholar
• Tham YL, Hinckley L, Teh BS, Elledge R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin. Breast. Cancer7(2), 164–166 (2006).
   PubMed Web of Science ®Google Scholar
• Navolanic PM, McCubrey JA. Pharmacological breast cancer therapy (review). Int. J. Oncol.27(5), 1341–1344 (2005).
   PubMed Web of Science ®Google Scholar
• Lassman AB, Abrey LE, Shah GG et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J. Neurooncol.78(3), 255–260 (2006).
   PubMed Web of Science ®Google Scholar
• Zulkowski K, Kath R, Semrau R, Merkle K, Hoffken K. Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J. Cancer Res. Clin. Oncol.128(2), 111–113 (2002).
   PubMed Web of Science ®Google Scholar
• Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res.51(18), 4837–4844 (1991).
   PubMed Web of Science ®Google Scholar
• Pors H, von Eyben FE, Sorensen OS, Larsen M. Longterm remission of multiple brain metastases with tamoxifen. J. Neurooncol.10(2), 173–177 (1991).
   PubMed Web of Science ®Google Scholar
• Salvati M, Cervoni L, Innocenzi G, Bardella L. Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases. Tumori79(5), 359–362 (1993).
   PubMed Web of Science ®Google Scholar
• Suh JH. Efaproxiral: a novel radiation sensitiser. Expert Opin. Investig. Drugs13(5), 543–550 (2004).
   PubMed Web of Science ®Google Scholar
• Suh JH, Stea B, Nabid A et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J. Clin. Oncol.24(1), 106–114 (2006).
   PubMed Web of Science ®Google Scholar
• Lin N, Carey, LA, Liu, MC et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. ASCO Annual Meeting Proceedings Part I 2006. J. Clin. Oncol.24, S18 (2006) (Abstract 503).
   Google Scholar
• Jacquillat C, Khayat D, Banzet P et al. Final report of the French multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer66(9), 1873–1878 (1990).
   PubMed Web of Science ®Google Scholar
• Kleeberg UR, Engel E, Israels P et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre Phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res.5(3), 195–200 (1995).
   PubMed Web of Science ®Google Scholar
• Mornex F, Thomas L, Mohr P et al. A prospective randomized multicentre Phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res.13(1), 97–103 (2003).
   PubMed Web of Science ®Google Scholar
• Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N. Engl. J. Med.345(8), 621–622 (2001).
   PubMed Web of Science ®Google Scholar
• Dvorak J, Melichar B, Zizka J, Hadzi-Nikolov D, Petera J. Complete response of multiple melanoma brain metastases after treatment with temozolomide. Onkologie27(2), 171–174 (2004).
   PubMedGoogle Scholar
• Paul MJ, Summers Y, Calvert AH et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res.12(2), 175–178 (2002).
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Kirkwood JM, Gore M et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a Phase II study. J. Clin. Oncol.22(11), 2101–2107 (2004).
   PubMed Web of Science ®Google Scholar
• Hofmann M, Kiecker F, Wurm R et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J. Neurooncol.76(1), 59–64 (2006).
   PubMed Web of Science ®Google Scholar
• Margolin K, Atkins B, Thompson A et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol.128(4), 214–218 (2002).
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Marples M, Napier MP, Meyer T, Boxall J, Rustin GJ. A Phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. Br. J. Cancer89(10), 1901–1905 (2003).
   PubMed Web of Science ®Google Scholar
• Bafaloukos D, Gogas H, Georgoulias V et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a Phase II study of the Hellenic Cooperative Oncology Group. J. Clin. Oncol.20(2), 420–425 (2002).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Panageas KS, Menell JH et al. Phase II study of temozolomide plus pegylated interferon-α-2b for metastatic melanoma. Cancer106(11), 2445–2451 (2006).
   PubMed Web of Science ®Google Scholar
• Pawlak WZ, Legha SS. Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res.14(1), 57–62 (2004).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol.21(17), 3351–3356 (2003).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol.2(10), 634–635 (2001).
   PubMed Web of Science ®Google Scholar
• Hwu W, Krown SE, Lis E et al. Phase II study of temozolomide (TMZ) plus thalidomide in patients with brain metastasis from malignant melanoma. Proc. Am. Soc. Clin. Oncol.22 (2003) (Abstract 2894).
   Google Scholar
• Schold SC, Vurgrin D, Golbey RB, Posner JB. Central nervous system metastases from germ cell carcinoma of testis. Semin. Oncol.6(1), 102–108 (1979).
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Samuels ML, Trindade A. The management of brain metastases in germ cell tumors. Cancer49(1), 12–18 (1982).
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Newlands ES, Bagshawe KD, Begent RH, Crawford SM. Successful management of metastatic and primary germ cell tumors in the brain. Cancer57(11), 2108–2113 (1986).
   PubMed Web of Science ®Google Scholar
• Raghavan D, Mackintosh JF, Fox RM, Rogers J, Duval P, Besser M. Improved survival after brain metastases in non-seminomatous germ cell tumours with combined modality treatment. Br. J. Urol.60(4), 364–367 (1987).
   PubMedGoogle Scholar
• Spears WT, Morphis JG, 2nd, Lester SG, Williams SD, Einhorn LH. Brain metastases and testicular tumors: long-term survival. Int. J. Radiat. Oncol. Biol. Phys.22(1), 17–22 (1992).
   PubMed Web of Science ®Google Scholar
• Mahalati K, Bilen CY, Ozen H, Aki FT, Kendi S. The management of brain metastasis in nonseminomatous germ cell tumours. Br. J. Urol. Int.83(4), 457–461 (1999).
   Google Scholar
• Bokemeyer C, Nowak P, Haupt A et al. Treatment of brain metastases in patients with testicular cancer. J. Clin. Oncol.15(4), 1449–1454 (1997).
   PubMed Web of Science ®Google Scholar
• Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L, Dent J. Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979–1984). Br. J. Obstet. Gynaecol.93(1), 63–69 (1986).
   PubMedGoogle Scholar
• Rustin GJ, Bagshawe KD. Gestational trophoblastic tumors. Crit. Rev. Oncol. Hematol.3(2), 103–142 (1985).
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Newlands ES, Begent RH, Dent J, Bagshawe KD. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J. Clin. Oncol.7(7), 900–903 (1989).
   PubMed Web of Science ®Google Scholar
• Soper JT, Evans AC, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB. Alternating weekly chemotherapy with etoposide–methotrexate–dactinomycin/cyclophosphamide–vincristine for high-risk gestational trophoblastic disease. Obstet. Gynecol.83(1), 113–117 (1994).
   PubMed Web of Science ®Google Scholar
• Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br. J. Obstet. Gynaecol.98(6), 550–557 (1991).
   PubMedGoogle Scholar
• Bower M, Newlands ES, Holden L et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J. Clin. Oncol.15(7), 2636–2643 (1997).
   PubMed Web of Science ®Google Scholar
• Sen DK, Sivanesaratnam V, Chuah CY, Ch'ng SL, Singh J, Paramsothy M. Cerebral metastases from choriocarcinoma. Results of chemotherapy. Acta. Obstet. Gynecol. Scand.66(5), 425–428 (1987).
   PubMed Web of Science ®Google Scholar
• Yordan EL, Jr., Schlaerth J, Gaddis O, Morrow CP. Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system. Obstet. Gynecol.69(4), 627–630 (1987).
   PubMed Web of Science ®Google Scholar
• Levitt LJ, Dawson DM, Rosenthal DS, Moloney WC. CNS involvement in the non-hodgkin’s lymphomas. Cancer45(3), 545–552 (1980).
   PubMed Web of Science ®Google Scholar
• Khuntia D, Mehta M. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev. Anticancer Ther.4(6), 981–989 (2004).
   PubMedGoogle Scholar
• Kristjansen PE, Soelberg Sorensen P, Skov Hansen M, Hansen HH. Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen. Ann. Oncol.4(7), 579–583 (1993).
   PubMed Web of Science ®Google Scholar
• Kristjansen PE, Hansen HH. Brain metastases from small cell lung cancer treated with combination chemotherapy. Eur. J. Cancer Clin. Oncol.24(3), 545–549 (1988).
   PubMedGoogle Scholar
• Twelves CJ, Souhami RL, Harper PG et al. The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br. J. Cancer61(1), 147–150 (1990).
   PubMed Web of Science ®Google Scholar
• Giaccone G, Donadio M, Bonardi GM, Testore F, Calciati A. Teniposide (VM26): an effective treatment for brain metastases of small cell carcinoma of the lung. Eur. J. Cancer Clin. Oncol.24(4), 629–631 (1988).
   PubMedGoogle Scholar
• Postmus PE, Smit EF, Haaxma-Reiche H et al. Teniposide for brain metastases of small-cell lung cancer: a Phase II study. European organization for research and treatment of cancer lung cancer cooperative group. J. Clin. Oncol.13(3), 660–665 (1995).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Dahrouge S. Response of brain metastases from breast cancer to megestrol acetate: a case report. J. Neurooncol.24(3), 299–301 (1995).
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Bafaloukos D, Linardou H et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J. Neurooncol.71(1), 61–65 (2005).
   PubMed Web of Science ®Google Scholar
• Oberhoff C, Kieback DG, Wurstlein R et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie24(3), 256–260 (2001).
   PubMedGoogle Scholar